Clinical Trial

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

Study acronym: MOMENTUM
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Enrollment increased: 36 -> 46 participants 2026-08-11
notable Primary completion pushed: 2026-06-30 -> 2026-12 2026-08-11
notable Trial sites expanded: 26 -> 41 locations 2026-06-24
Trial Details
NCT Number NCT06537999
Lead Sponsor Dianthus Therapeutics
Conditions Multifocal Motor Neuropathy
Enrollment 46 participants
Start Date 2024-09-17
Primary Completion 2026-12 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10